Chronic Infusion of Bradykinin Delays the Progression of Heart Failure and Preserves Vascular Endothelium-Mediated Vasodilation in Conscious Dogs

Circulation

Volumn 109, Issue 1, 2004, Pages 114-119

  Tonduangu, Daniel ^a   Hittinger, Luc ^a   Ghaleh, Bijan ^b   Le Corvoisier, Philippe ^a   Sambin, Lucien ^a   Champagne, Stéphane ^a   Badoual, Thierry ^a   Vincent, Fanny ^a   Berdeaux, Alain ^b   Crozatier, Bertrand ^a   Su, Jin Bo ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b INSERM   (France)

Author keywords

Bradykinin; Endothelium; Heart failure

Indexed keywords

ACETYLCHOLINE; BRADYKININ; GLYCERYL TRINITRATE; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAROTID ARTERY; CONSCIOUSNESS; CONTROLLED STUDY; DOG; DRUG INFUSION; FEMORAL ARTERY; HEART FAILURE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE VOLUME; HEART OUTPUT; HEART VENTRICLE CONTRACTION; HEART VENTRICLE HYPERTROPHY; HEMODYNAMICS; HORMONE ACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL ARTERY; SYSTOLE; VASCULAR ENDOTHELIUM; VASODILATATION; WESTERN BLOTTING;

EID: 0347357879     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000105726.89770.35     Document Type: Article

References (26)

1. Mombouli J-V, Vanhoutte PM. Kinins and endothelial control of vascular smooth muscle. Ann Rev Pharmacol Toxicol. 1995;35:679-705.
2. Su JB, Barbe F, Crozatier B, et al. Increased bradykinin levels accompany the hemodynamic response to acute inhibition of angiotensin-converting enzyme in dogs with heart failure. J Cardiovasc Pharmacol. 1999;34:700-710.
3. Barbe F, Su JB, Guyene TT, et al. Bradykinin pathway is involved in the acute hemodynamic effects of enalaprilat in dogs with heart failure. Am J Physiol. 1996;270:H1985-H1992.
4. Su JB, Barbe F, Houel R, et al. Preserved vasodilator effect of bradykinin in conscious dogs with heart failure. Circulation. 1998;98:2911-2918.
5. Witherow FN, Helmy A, Webb DJ, et al. Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Circulation. 2001;104:2177-2181.
6. Groves P, Kurz S, Just H, et al. Role of endogenous bradykinin in human coronary vasomotor control. Circulation. 1995;92:3424-3430.
7. Prasad A, Husain S, Quyumi AA. Abnormal flow-mediated epicardial vasomotion in human coronary arteries is improved by angiotensin-converting enzyme inhibition: a potential role of bradykinin. J Am Coll Cardiol. 1999;33:796-804.
8. Nikolaidis LA, Doverspike A, Huerbin R, et al. Angiotensin-converting enzyme inhibitors improve coronary flow reserve in dilated cardiomyopathy by a bradykinin-mediated, nitric oxide-dependent mechanism. Circulation. 2002;105:2785-2790.
9. Kuro SH, Rector TS, Bank AJ, et al. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation. 1991;84:1589-1596.
10. Katz SD, Schwarz M, Yuen J, et al. Impaired acetylcholine-mediated vasodilation in patients with congestive heart failure: role of endothelium-derived vasodilating and vasoconstricting factors. Circulation. 1993;88:55-61.
11. Kiuchi K, Sato N, Shannon RP, et al. Depressed β-adrenergic receptor-and endothelium-mediated vasodilation in conscious dogs with heart failure. Circ Res. 1993;73:1013-1023.
12. Cheng C-P, Onishi K, Ohte N, et al. Functional effects of endogenous bradykinin in congestive heart failure. J Am Coll Cardiol. 1998;31:1679-1686.
13. Emanueli C, Maestri R, Corradi D, et al. Dilated and failing cardiomyopathy in bradykinin B2 receptor knockout mice. Circulation. 1999;100:2359-2365.
14. Houel R, Su JB, Barbe F, et al. Regional myocardial effects of intracoronary bradykinin in conscious dogs. Am J Physiol. 1997;272: H1266-H1274.
15. Komamura K, Shannon RP, Passipoularides A, et al. Alterations in left ventricular diastolic function in conscious dogs with pacing-induced heart failure. J Clin Invest. 1992;89:1825-1838.
16. Spinale FG, Coker ML, Krombach SR, et al. Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function. Circ Res. 1999;85:364-376.
17. Xie Y-W, Shen W, Zhao G, et al. Role of endothelium-derived nitric oxide in the modulation of canine myocardial mitochondrial respiration in vitro. Circ Res. 1996;79:381-387.
18. Fujii M, Wada A, Tsutamoto T, et al. Bradykinin improves left ventricular diastolic function under long-term angiotensin-converting enzyme inhibition in heart failure. Hypertension. 2002;39:952-957.
19. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure, part 1. Circulation. 2002;105:1387-1393.
20. Drexler H. Endothelium as a therapeutic target in heart failure. Circulation. 1998;98:2652-2655.
21. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing Endothelial Dysfunction) study. Circulation. 1996;94:258-265.
22. Hornig B, Arakawa N, Haussmann D, et al. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. Circulation. 1998;98:2842-2848.
23. Bachetti T, Comini L, Pasini E, et al. ACE-inhibition with quinapril modulates the nitric oxide pathway in normotensive rats. J Moll Cell Cardiol. 2001;33:395-403.
24. Loke KE, Laycock SK, Mital S, et al. Nitric oxide modulates mitochondrial respiration in failing human heart. Circulation. 1999;100:1291-1297.
25. Regoli D, Barabé J. Pharmacology of bradykinin and related kinins. Pharmacol Rev. 1980;32:1-46.
26. 1 receptors induces vasodilation in conductance and resistance coronary vessels in conscious dogs: comparison with B2 receptor stimulation. Circulation. 2000;101:184-1853.